title: Response by Hänggi and Macdonald to Letter Regarding Article, "Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage])".
authors.affiliation: Department of Neurosurgery, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Germany.
authors.forename: Daniel
authors.initials: D
authors.lastname: Hänggi
authors.affiliation: Division of Neurosurgery, St. Michael's Hospital, Labatt Family Centre of Excellence in Brain Injury and Trauma Research, Keenan Research Centre for Biomedical Research and Li Ka Shing Knowledge Institute, Department of Surgery, University of Toronto, Canada.
authors.forename: R Loch
authors.initials: RL
authors.lastname: Macdonald
mesh_terms: D003692:Delayed-Action Preparations; D006801:Humans; D020714:Maximum Tolerated Dose; D009553:Nimodipine; D013345:Subarachnoid Hemorrhage; D014665:Vasodilator Agents; D020301:Vasospasm, Intracranial
chemical_list: D003692:Delayed-Action Preparations; D014665:Vasodilator Agents; D009553:Nimodipine